HC Wainwright began coverage on shares of Mainz Biomed B.V. (NASDAQ:MYNZ – Get Rating) in a research note released on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $25.00 price objective on the stock.
MYNZ opened at $9.60 on Tuesday. Mainz Biomed B.V. has a 12-month low of $7.80 and a 12-month high of $30.00. The business’s fifty day simple moving average is $11.61 and its 200-day simple moving average is $13.31.
An institutional investor recently bought a new position in Mainz Biomed B.V. stock. Greenwich Investment Management Inc. purchased a new position in shares of Mainz Biomed B.V. (NASDAQ:MYNZ – Get Rating) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 14,724 shares of the company’s stock, valued at approximately $215,000.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests.
Further Reading
- Get a free copy of the StockNews.com research report on Mainz Biomed B.V. (MYNZ)
- Are These Cheap Copper Stocks Right For Your Portfolio?
- Zai Lab Stock Has Fallen to Value Levels
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Mainz Biomed B.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed B.V. and related companies with MarketBeat.com's FREE daily email newsletter.
